MedTrace Logo

Safety and Tolerability of Oral CM082 in Patients With wAMD

NCT03710863 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-01-13

No results posted yet for this study

Summary

This is a Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Intermittent Oral Dosing of CM082 tablets in Chinese Patients With wAMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

CM082

Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.

Sponsors & Collaborators

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • AnewPharma

    lead INDUSTRY

Principal Investigators

  • Yin Shen · Renmin Hospital of Wuhan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-22
Primary Completion
2022-01-01
Completion
2022-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710863 on ClinicalTrials.gov